NLRP3 and Parkinson disease: Research has shown that α-synuclein can promote NLRP3 inflammasome activation in PD models, and further studies have revealed that α-synuclein increases the levels of cathepsin B and ROS, thus triggering NLRP3 inflammasome activation (Codolo et al., 2013; Chatterjee et al., 2020).